Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Genzyme, a Sanofi Company262 enrolled

Overview

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Study Type

OBSERVATIONAL

Enrollment

262

Conditions

Bone Marrow / Autologous Transplants

Interventions

PlerixaforDRUG

Plerixafor will be prescribed independently by the physician, according to usual practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012 * Patients who have been informed and who have given their written consent for the access to their medical file Exclusion Criteria: * Patients already included in a Plerixafor ongoing clinical trial.

Locations (1)

Unnamed facility

Marseille, France

Outcomes

Primary Outcomes

The characteristics of the patients who received treatment

Time frame: 13 months

Dosage of treatment

Time frame: 13 months

Number of CD34+ cells collected following treatment

Time frame: 13 months

Number of patients with the existence of one or more predictive factors of poor mobilisation

Time frame: 13 months

Duration of treatment

Time frame: 13 months

Associated treatments

Time frame: 13 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.